Investor Presentation First Nine Months of 2023

67 Investor presentation First nine months of 2023 In STEP 5, people treated with semaglutide 2.4 mg sustained their weight loss over 2 years % change in body weight Clinically relevant and sustained weight loss in patients with obesity or overweight 0 2 4 6∞ -2 -10 -12 -14 -16 -18 -20 Data from STEP 5 40% of patients lost ≥ 20% of their body weight Placebo: -0.6% Semaglutide 2.4 mg: -16.7% 0 8 16 24 32 40 48 56 64 72 80 88 96 104 Time since initiation (weeks) Change in body weight in % depicts observed means since time of randomisation; trial product estimand; mean body weight: 106.0 kg Semaglutide appeared to have a safe and well-tolerated profile Improvements in lipid profiles as well as C- reactive protein Novo NordiskⓇ

View entire presentation